Caldera Medical, a women’s health device company, has acquired Johnson & Johnson MedTech’s Gynecare TVT family of products, a suite of minimally invasive treatment options for women with stress urinary incontinence (SUI).

The TVT product line—which consists of TVT, TVT Exact, TVT-O, and TVT Abbrevo—tout over two decades of clinical data. This includes 20-year patient followup. The products are intended to be used in women as pubourethral slings to treat SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency.

Caldera said it will maintain the same manufacturing facility, materials, and manufacturing team behind the TVT products. The company will also expand global customer support for TVT over the next few months and invest in advancing care for more women.

This acquisition follows the company’s September 2023 buy of Atlantic Therapeutics with the Innovo non-invasive solution for bladder leaks and the October 2024 purchase of UVision360 with the Luminelle product line for hysteroscopy and cystoscopy.

“This acquisition marks a significant advancement in our mission to transform women’s health,” said Bryon Merade, CEO of Caldera Medical. “By bringing the TVT product line into our portfolio, we reinforce our unwavering commitment to providing safe, effective solutions for surgeons and their patients. We are honored to build on the legacy and expand the reach of this esteemed product family, delivering proven treatments to more women around the world.”